Hope for a reliable, early detection test
Phase III evaluations have begun on a blood test developed by
researchers out of the Yale School of Medicine. So far the test has
detected newly diagnosed ovarian cancer with 99.4 percent accuracy by
using six protein biomarkers. “We hope this test will become the
standard of care for women having routine examinations,” says lead
author Gil Mor, M.D., associate professor at the department of
Obstetrics, Gynecology and Reproductive Sciences at Yale.
The test requires further study and extended follow-up with more
patients, however the news represents an encouraging development in the
search for a reliable, early detection test for ovarian cancer. Results
from the phase II clinical trials were published in the February 15
issue of the journal Clinical Cancer Research.
noticed you had acor listed. do you still belong to the group? I do. Update me on your health. I am so sorry about your parents.
Patsy
stage IIIc survivor
This is such promising news.